Highlights Orthocell Limited

Stocks

OCC

AU000000OCC6

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 11:40:16 12/06/2026 am IST			5-day change	1st Jan Change
0.7350 ^AUD	-1.34%		-3.29%	-32.26%

30/04	Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada	MT
28/04	Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%	MT

Highlights

20/04	Orthocell says qtrly A$3.2 million revenue achieved	RE
16/04	Orthocell Limited Secures Approval for Remplir Nerve Repair Device to Be Used Across United States Department of Defence and Veterans Affairs Hospital Networks	CI
15/04	Orthocell Wins Approval for Nerve Repair Device Across US Military, VA Hospital Networks	MT
10/03	Orthocell Names UK Distributor For Nerve Repair Product, Shares Jump 3%	MT
24/02	Orthocell Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
19/01	Orthocell posts quarterly revenue of A$3.2 million	RE
16/01	Orthocell Finalizes Agreement With Biotechnology Company	MT
06/01	Orthocell posts A$3.2 million in revenue for quarter ended 31 December	RE
15/12	Orthocell Submits Application to the British Standards Institution for Approval for Commercial Distribution of Nerve Repair Product, Shares Up 3%	MT
15/12	Orthocell submits regulatory application for commercial distribution of Remplir	RE
10/12	Orthocell Sells Nerve Repair Product in Hong Kong	MT
20/11	Orthocell Limited Announces Adoption of Remplir by Australian Urologists	CI
20/11	Orthocell To Set Up Commercialization Advisory Board for Nerve Repair Product, Shares Up 7%	MT
05/11	Orthocell Appoints Second Distributor in Canada for Nerve Repair Product	MT
29/25/29	Orthocell Appoints MontsMed as Exclusive Distributor for Remplir in Hong Kong	MT
29/25/29	Orthocell Appoints MontsMed as Its Exclusive In-Country Distributor for Hong Kong	CI
20/25/20	Orthocell secures rights to high-value bone regeneration tech	RE
20/25/20	Orthocell Signs MoU with Biotechnology Company; Shares Up 3%	MT
10/25/10	Orthocell Ltd reports quarterly revenue of A$3.0 million	RE
03/25/03	Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says	MT
02/25/02	Orthocell Ltd says revenue of A$3.0 mln achieved for quarter ended 30 Sept	RE
30/25/30	Orthocell Appoints First Canadian Distributor for Nerve Repair Product Ahead of Official Launch; Shares Soar 13%	MT
16/25/16	Orthocell Limited Announces Nerve-Sparing Prostate Cancer Surgery	CI
29/25/29	Orthocell Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
29/25/29	Orthocell Posts Wider Fiscal 2025 Loss, Higher Revenue	MT